LUCD

Lucid Diagnostics Inc. (LUCD) Business Model Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Revenue Quality

Revenue base remains very small at $0.03 per share, but the company continues to generate sales with no dividend burden.

Gross margin is still negative at -25.8%, indicating the core product mix has not yet reached profitability.

Profitability

Operating performance remains deeply negative, with EBIT margin at -9.6% and net profit margin at -9.6%.

Returns remain poor, with ROA at -1.34% and ROE at -4.04%, showing no meaningful profitability improvement.

Cash Flow

Operating cash flow and free cash flow remain negative, with FCF per share at -$0.26 and FCF yield at -24.9%.

Cash generation is still insufficient to cover operations, despite capex remaining minimal relative to cash flow.

Balance Sheet

Liquidity remains acceptable with a current ratio of 1.33 and quick ratio of 1.31.

Leverage is manageable for now, with debt-to-equity at 2.28 and net debt to EBITDA near 0.17.

Capital Efficiency

Asset efficiency remains weak, with asset turnover at 0.14 and ROIC at -1.41%.

Working capital is positive at $9.1M, but the business is still not converting capital into returns effectively.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lucid Diagnostics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →